PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative marine-derived drugs. 

PharmaMar develops and commercializes Yondelis® (trabectedin) in Europe for the treatment of advanced soft tissue sarcoma (STS). Yondelis® is a synthetic antineoplastic drug originally isolated from the marine tunicate Ecteinascidia turbinata. Yondelis is indicated for the treatment of adult patients with advanced STS, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis#product-information-section